45,976 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 45,976 shares of the company’s stock, valued at approximately $6,521,000.

Other institutional investors also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Neurocrine Biosciences by 11.0% in the third quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock valued at $664,019,000 after buying an additional 468,405 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Neurocrine Biosciences by 83.7% in the third quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock valued at $388,435,000 after buying an additional 1,263,633 shares in the last quarter. Deerfield Management Company L.P. raised its position in shares of Neurocrine Biosciences by 1.4% in the third quarter. Deerfield Management Company L.P. now owns 1,184,345 shares of the company’s stock valued at $166,258,000 after buying an additional 16,543 shares in the last quarter. UBS Group AG raised its position in shares of Neurocrine Biosciences by 169.8% in the fourth quarter. UBS Group AG now owns 983,528 shares of the company’s stock valued at $139,494,000 after buying an additional 618,956 shares in the last quarter. Finally, Pictet Asset Management Holding SA raised its position in shares of Neurocrine Biosciences by 12.0% in the fourth quarter. Pictet Asset Management Holding SA now owns 776,934 shares of the company’s stock valued at $110,305,000 after buying an additional 83,488 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 245,088 shares of the company’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $154.33, for a total transaction of $37,824,431.04. Following the sale, the director owned 511,293 shares of the company’s stock, valued at approximately $78,907,848.69. This represents a 32.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard F. Pops sold 15,000 shares of the company’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the sale, the director directly owned 34,480 shares in the company, valued at $5,435,772. This trade represents a 30.32% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 263,898 shares of company stock valued at $40,779,769 over the last 90 days. 4.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Morgan Stanley lifted their price target on shares of Neurocrine Biosciences from $185.00 to $191.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Truist Financial lifted their price target on shares of Neurocrine Biosciences from $140.00 to $155.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Zacks Research upgraded shares of Neurocrine Biosciences from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 15th. Sanford C. Bernstein assumed coverage on shares of Neurocrine Biosciences in a research report on Friday. They issued an “outperform” rating and a $221.00 price target for the company. Finally, Royal Bank Of Canada lifted their price target on shares of Neurocrine Biosciences from $176.00 to $180.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $185.90.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX opened at $156.70 on Tuesday. The firm’s fifty day moving average price is $137.25 and its two-hundred day moving average price is $138.97. The stock has a market cap of $15.76 billion, a PE ratio of 24.14, a PEG ratio of 1.18 and a beta of 0.34. Neurocrine Biosciences, Inc. has a fifty-two week low of $117.59 and a fifty-two week high of $162.39.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.